Publications

• A.E. Attema, O. l'Haridon & G. van de Kuilen (2019). Measuring multivariate risk preferences in the health domain. Journal of Health Economics, 64, 15-24. doi: 10.1016/j.jhealeco.2018.12.004[go to publisher's site]
• A.E. Attema, L. He, A.J.C. Cook & V.J. Del Rio Vilas (2019). Unbiased assessment of disease surveillance utilities: a prospect theory application. PLoS Neglected Tropical Diseases (online), 13 (5):e0007364. doi: 10.1371/journal.pntd.0007364 [go to publisher's site]
• S.A. Lipman & A.E. Attema (2019). Rabin's Paradox for Health Outcomes. Health Economics, 28 (8), 1064-1071. doi: 10.1002/hec.3918 

• S. Neelsen, S. Limwattananon, O.A. O'Donnell & E.K.A. van Doorslaer (2019). Universal health coverage: A (social insurance) job half done? World Development, 113, 246-258. doi: 10.1016/j.worlddev.2018.09.004
• L.R. Buisman, E. Van de Poel, O.A. O'Donnell & E. van Doorslaer (2019). What explains the fall in child stunting in Sub-Saharan Africa? SSM - Population Health, 8:100384. doi: 10.1016/j.ssmph.2019.100384
• E.K.A. van Doorslaer, L.E.M. Koomen & R. Burger (2019). Effects and determinants of tuberculosis drug stockouts in South Africa. Bmc Health Services Research, 19 (213). doi: 10.1186/s12913-019-3972-x
• H. Zhang, E.K.A. van Doorslaer & J.J. van de Klundert (2019). Can a Bottom-up Results-based Reform Project Improve Health System Performance? Health Economics. doi: 10.1002/hec.3935
• Wagstaff, E.K.A. van Doorslaer & R. Burger (2019). SMS nudges as a tool to reduce tuberculosis treatment delay and pretreatment loss to follow-up. A randomized controlled trial. PLoS One (online), 20. doi: 10.1371/journal.pone.0218527
• M. Fikru Rizal & E.K.A. van Doorslaer (2019). Explaining the fall of socioeconomic inequality in childhood stunting in Indonesia. SSM - Population Health, 9:100469. doi: 10.1016/j.ssmph.2019.100469
• M.H. Coveney, P. Garcia Gomez, E.K.A. van Doorslaer & T.G.M. Van Ourti (2019). Thanks goodness for stickiness. Unravelling the evolution of income-related health inequalities before and after the Great recession in Europe. Journal of Health Economics.
• L.E.M. Koomen, R. Burger & E.K.A. van Doorslaer (2019). Effects and determinants of tuberculosis drug stockouts in South Africa. Bmc Health Services Research, 19:213. doi: 10.1186/s12913-019-3972-x

S. Rellstab, P.L.H. Bakx, P. Garcia-Gomez & E.K.A. van Doorslaer (2019). The kids are alright - labour market effects of unexpected parental hospitalisations in the Netherlands. Journal of Health Economics, accepted. doi: 10.1016/j.jhealeco.2019.102275

• J.A.M. Bom, P.L.H. Bakx, F.T. Schut & E.K.A. van Doorslaer (2019). Health effects of caring for and about parents and spouses. Journal of the Economics of Ageing, 14. doi: 10.1016/j.jeoa.2019.100196
• M. Gheorghe, R.J. Hoefman, M.M. Versteegh & J. van Exel (2019). Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool. Pharmacoeconomics (Print), 37 (1), 93-103. doi: 10.1007/s40273-018-0706-6
• C. Brown, J.M. Tilford, N. Payakachat, K. Williams, K.A. Kuhlthau, J.M. Pyne, R.J. Hoefman & W.B.F. Brouwer (2019). Measuring Caregiver Spillover Effects Associated with Autism Spectrum Disorder: A Comparison of the EQ-5D-3L and SF-6D. Pharmacoeconomics (Print), 37 (4), 609-620.
• P. baji, D. Golicki, V. Prevolnik-Rupel, W.B.F. Brouwer, Z. Zrubka, L. Gulacsi & M. Pentek (2019). The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. The European Journal Of Health Economics, 20 (S1), 5-16.
• R.J. Hoefman, N.J.A. Van Exel & W.B.F. Brouwer (2019). The monetary valuation of informal care: obtaining pure time valuations using a Discrete Choice Experiment. Pharmacoeconomics (Print), 37 (4), 531-540.
• M.S. Perry-Duxbury, N.J.A. Van Exel, W.B.F. Brouwer, A. Sköldunger, M. Gonçalves‑Pereira, K. Irving, G. Meyer, G. Selbaek, B. Woods, O. Zanetti, F. Verhey, A. Wimo & R.L.H. Handels (2019). A validation study of the ICECAP‑O in informal carers of people with dementia from eight European Countries. Quality of Life Research, 1-15. doi: 10.1007/s11136-019-02317-3
• L. Ten Hoopen, P.F.A. De Nijs, J. Duvekot, K. Greaves-Lord, M.H.J. Hillegers, W.B.F. Brouwer & L. Hakkaart - van Roijen (2019). Children with an autism spectrum disorder and their caregivers: capturing health-related and care-related quality of life. Journal of Autism and Developmental Disorders, 49 (323), 1-15. doi: 10.1007/s10803-019-04249-w

• A.A.H. de Hond, P.L.H. Bakx & M.M. Versteegh (2019). Can time heal all wounds? An empirical assessment of adaptation to functional limitations in an older population. Social Science & Medicine, 222, 180-187. doi: 10.1016/j.socscimed.2018.12.028 [go to publisher's site]
• E.K.A. van Doorslaer, L.E.M. Koomen & R. Burger (2019). Effects and determinants of tuberculosis drug stockouts in South Africa. Bmc Health Services Research, 19 (213). doi: 10.1186/s12913-019-3972-x
• S.A. Lipman, W.B.F. Brouwer & A.E. Attema (2019). A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health states. European Journal of Health Economics (HEPAC), 20 (3), 419-426. doi: 10.1007/s10198-018-1008-9 [go to publisher's site]
• Versteegh MM, Attema AE, Uyl-de Groot CA (2019). Is verlies winst? Stoppen met TNF-alfaremmers. Nederlands Tijdschrift voor Geneeskunde, 163:D3709.
• M.M. Versteegh, I. Corro Ramos, N.C. Buyukkaramikli, A. Ansaripour, V.T. Reckers - Droog & W.B.F. Brouwer (2019). Severity-Adjusted Probability of Being Cost Effective. Pharmacoeconomics (Print). doi: 10.1007/s40273-019-00810-8
• M.S. Perry-Duxbury, N.J.A. Van Exel & W.B.F. Brouwer (2019). How to value safety in economic evaluations in health care? A review of applications in different sectors. The European Journal Of Health Economics. doi: 10.1007/s10198-019-01076-9
• S.A. Lipman, W.B.F. Brouwer & A.E. Attema (2019). The corrective approach: policy implications of recent developments in QALY measurement based on prospect theory. Value in Health.
• S.A. Lipman, W.B.F. Brouwer & A.E. Attema (2019). QALYs without bias? Non-parametric correction of time trade-off and standard gamble weights based on prospect theory. Health Economics, 28 (7), 843-854. doi: 10.1002/hec.3895
• F.C.W. van Krugten, M. Goorden, A.J.L.M. van Balkom, P. van Oppen, D.J.F. van Schaik, W.B.F. Brouwer & L. Hakkaart-van Roijen (2019). The decision tool unipolar depression (DTUD): a new measure to facilitate the early identification of patients with major depressive disorder in need of highly specialized care. BMC Psychiatry, 19 (179). doi: 10.1186/s12888-019-2165-9
• J.L. Pinto-Prades, A.E. Attema & F.I. Sanchez-Martinez (2019). Measuring Health Utility in Economics. In Oxford Research Encyclopedia of Economics and Finance. Oxford: Oxford University Press
• L.R. Buisman, A.J. Rijnsburger, A. Van der Lugt, P.J. Nederkoorn, P.J. Koudstaal & W.K. Redekop (2019). Cost-effectiveness of novel imaging tests to select patients for carotid endarterectomy. Health Policy and Technology, 8 (2), 111-117. doi: 10.1016/j.hlpt.2019.05.001
• W.B.F. Brouwer, P.H.M. van Baal, N.J.A. Van Exel & M.M. Versteegh (2019). When is it too expensive? Cost-effectiveness thresholds and health care decision making. The European Journal Of Health Economics, 20 (2), 175-180.
• M.Q.N. Hackert, N.J.A. Van Exel & W.B.F. Brouwer (2019). Does the ICECAP-O cover the Physical, Mental and Social Functioning of Older People in the UK? Quality of Life Research, 28, 761-770.
• P.H.M. van Baal, A. Morton, D. Meltzer & W.B.F. Brouwer (2019). Future unrelated medical costs need to be considered in cost effectiveness analysis. The European Journal Of Health Economics, 20, 1-5.
• P.H.M. van Baal, M. Perry-Duxbury, P.L.H. Bakx, M.M. Versteegh, E.K.A. van Doorslaer & W.B.F. Brouwer (2019). A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. Health Economics, 28 (1), 87-100.
• L. De Vries, P.H.M. van Baal & W.B.F. Brouwer (2019). Future costs in economic evaluations: past, present, future. Pharmacoeconomics (Print), 37 (2), 119-130.
• S. Knies, J.L. Severens & W.B.F. Brouwer (2019). Integrating clinical and economic evidence in clinical guidelines: More needed than ever! Journal of Evaluation in Clinical Practice, 25 (4), 561-564.
• W.B.F. Brouwer (2019). The inclusion of spill-over effects in economic evaluations: Not an optional extra. Pharmacoeconomics (Print), 37 (4), 451-456.
• R. van Elk, B. ter Weel, K. van der Wiel & B. Wouterse (2019). Estimating the Returns to Public R&D Investments: Evidence from Production Function Models. De Economist, 167 (1), 45-87. doi: 10.1007/s10645-019-09331-3
• M.G. Franken, B. Leeneman, M. Gheorghe, C.A. Uyl - de Groot, J. Haanen & P.H.M. van Baal (2019). A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European Journal of Cancer, 123, 58-71. doi: 10.1016/j.ejca.2019.08.032
• J. Brugts, J. Veenis, S.P. Radhoe, G. LInsssen, M. Van Gent, C.J.W. Borleffs, J. van Ramhorst, P. van Pol, R. Tukkie, R. Spee, M. Emans, W. Kok, V. van Halm, L. Handoko, S. Beeres, M. Post, E. Boersma, M.J. Lenzen, O.C. Manintveld, H. Koffijberg, P.H.M. van Baal, M.M. Versteegh, T. Smilde, L. van Heerebeek, M. Rienstra, A. Mosterd, P. Delnoy, F.W. Asselbergs, H. Brunner-La Rocca & R. de Boer (2019). A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure : Design and rationale of the MONITOR HF multicentre randomised clinical trial. Netherlands Heart Journal. doi: 10.1007/s12471-019-01341-9
• S. Ratushnyak, M. Hoogendoorn & P.H.M. van Baal (2019). Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained. American Journal of Preventive Medicine, 57 (6), 792-799. doi: 10.1016/j.amepre.2019.07.027

• F.E. van Nooten (2019, maart 21). The person behind the TTO : exploring what influences TTO responses. EUR Prom./coprom.: prof. W.B.F. Brouwer & prof. N.J.A. van Exel.

• V.T. Reckers - Droog, N.J.A. Van Exel & W.B.F. Brouwer (2019). Equity Weights for Priority Setting in Healthcare: Severity, Age, or Both? Value in Health. doi: 10.1016/j.jval.2019.07.012 
• M.M. Versteegh, I. Corro Ramos, N.C. Buyukkaramikli, A. Ansaripour, V.T. Reckers - Droog & W.B.F. Brouwer (2019). Severity-Adjusted Probability of Being Cost Effective. Pharmacoeconomics (Print). doi: 10.1007/s40273-019-00810-8 
• V.T. Reckers - Droog, M. Jansen, L. Bijlmakers, R.M.P.M. Baltussen, W.B.F. Brouwer & N.J.A. Van Exel (2019). How does participating in a deliberative citizens panel on healthcare priority setting influence the views of participants? Health Policy. doi: 10.1016/j.healthpol.2019.11.011

• A.E. Attema, H. Bleichrodt & O. l'Haridon (2018). Ambiguity preferences for health. Health Economics, 27 (11), 1699-1716. doi: 10.1002/hec.3795
• A.E. Attema, H. Bleichrodt, O. l'Haridon, P. Peretti-Watel & V. Seror (2018). Discounting health and money: New evidence using a more robust method. Journal of Risk and Uncertainty, 56 (2), 117-140. doi: 10.1007/s11166-018-9279-1
• A.E. Attema & S.A. Lipman (2018). Decreasing impatience for health outcomes and its relation with healthy behavior. Frontiers in Applied Mathematics and Statistics, 4, 1-8. doi: 10.3389/fams.2018.00016

• K. Haal, A. Smith & E.K.A. van Doorslaer (2018). The rise and fall of mortality inequality in South Africa in the HIV era. SSM - Population Health, 5, 239-248.
• L. Rossouw, T.M. Marreiros Bago d'Uva & E.K.A. van Doorslaer (2018). Poor Health Reporting? Using Anchoring Vignettes to Uncover Health Disparities by Wealth and Race. Demography, 55, 1935-1956. doi: 10.1007/s13524-018-0709-0
• K. Haal, A. Smith & E.K.A. van Doorslaer (2018). The rise and fall of mortality inequality in South Africa in the HIV era. SSM - Population Health, 5, 239-248.
• L. Rossouw, T.M. Marreiros Bago d'Uva & E.K.A. van Doorslaer (2018). Poor Health Reporting? Using Anchoring Vignettes to Uncover Health Disparities by Wealth and Race. Demography, 55, 1935-1956. doi: 10.1007/s13524-018-0709-0
• I.E.J. Bonfrer, E. Van de Poel, E. Gustafsson-Wright & E.K.A. van Doorslaer (2018). Voluntary health insurance in Nigeria: Effects on takers and non-takers. Social Science & Medicine, 205, 55-63.
• Wagstaff, G. Flores, J. Hsu, M. Smitz, K. Chepynoga, L.R. Buisman, K. Van Wilgenburg & P. Eozenou (2018). Progress on catastrophic health spending in 133 countries: a retrospective observational study. The Lancet Global Health, 6 (2), e169-e179. doi: http://dx.doi.org/10.1016/S2214-109X(17)30429-1

• B. Ravesteijn, J.L.W. van Kippersluis & E.K.A. van Doorslaer (2018). The Wear and Tear on Health: What is the Role of Occupation? Health Economics, 27 (2), e69-e86.
• M.N. Wagener, L.W.J. van den Dries, N.J.A. van Exel, H.S. Miedema, E.C.M. van Gorp & P.D.D.M. Roelofs (2018). Determinants of Employment in People Living with HIV in the Netherlands. Journal of Occupational Rehabilitation. doi: https://doi.org/10.1007/s10926-016-9692-8
• K. Verbooy, M.N. Wagener, M. Kaddouri, P.D.D.M. Roelofs, H. Miedema, E. van Gorp, W. Brouwer & J. van Exel (2018). Are people living with HIV less productive at work? Aids Care-Psychological and Socio-Medical Aspects of Aids/Hiv, 30 (10), 1265-1272. doi: 10.1080/09540121.2018.1447076
• K. Verbooy, M.N. Wagener, M. Kaddouri, P.D.D.M. Roelofs, H. Miedema, E. van Gorp, W. Brouwer & J. van Exel (2018). Are people living with HIV less productive at work? Aids Care-Psychological and Socio-Medical Aspects of Aids/Hiv, 30 (10), 1265-1272. doi: 10.1080/09540121.2018.1447076

• J.A.M. Bom, P.L.H. Bakx, F.T. Schut & E.K.A. van Doorslaer (2018). The Impact of Informal Caregiving for Older Adults on the Health of Various Types of Caregivers: A Systematic Review.The Gerontologist. doi: 10.1093/geront/gny137
• R.J. Hoefman, N.J.A. van Exel & W.B.F. Brouwer (2018). The monetary valuation of informal care: obtaining pure time valuations using a Discrete Choice Experiment. Pharmacoeconomics (Print). doi: 10.1007/s40273-018-0724-4
• K. Verbooy, R.J. Hoefman, N.J.A. van Exel & W.B.F. Brouwer (2018). Time is money: Investigating the value of leisure time and unpaid work.Opent extern Value in Health, 21 (12), 1428-1436. doi: 10.1016/j.jval.2018.04.1828

• F.E. van Nooten, J.J. van Busschbach, M. Agthoven, N.J.A. van Exel & W.B.F. Brouwer (2018). What should we know about the person behind a TTO? The European Journal Of Health Economics, 19 (9), 1207-1211. doi: 10.1007/s10198-018-0975-1
• M. Ruggeri, C. Drago, V. Moramarco, S. Coretti, J. Köppen, K. Islam, J. Gibson, R. Busse, N.J.A. van Exel, M. Sutton, J.E. Askildsen, C.M. Bond & R.F. Elliot (2018). New professional roles and patient satisfaction: Evidence from a European survey along three clinical pathways.Health Policy, 122(10), 1078-1084. doi: 10.1016/j.healthpol.2018.07.020
• P.H.M. van Baal, M.S. Perry-Duxbury, P.L.H. Bakx, M.M. Versteegh, E.K.A. van Doorslaer & W.B.F. Brouwer (2018). A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending.Health Economics, 28 (1), 87-100. doi: 10.1002/hec.3831
• S. Knies, J.L. Severens & W.B.F. Brouwer (2018). Integrating clinical and economic evidence in clinical guidelines: More needed than ever! Journal of Evaluation in Clinical Practice.
• W.B.F. Brouwer (2018). The inclusion of spill-over effects in economic evaluations: Not an optional extra.Pharmacoeconomics (Print).
• M.Q.N. Hackert, N.J.A. Van Exel & W.B.F. Brouwer (2018). Does the ICECAP-O cover the Physical, Mental and Social Functioning of Older People in the UK? Quality of Life Research.
• L.M. de Vries, P.H.M. van Baal & W.B.F. Brouwer (2018). Future Costs in Cost-Effectiveness Analyses: Past. Present, Future. Pharmacoeconomics (Online). doi: 10.1007/s40273-018-0749-8
• A.E. Attema, W.B.F. Brouwer & J.L. Pinto-Prades (2018). Peer effects in health valuation: The relation between rating of contemporaries' health and own health. Health and Quality of Life Outcomes, 16 (1):148. doi: 10.1186/s12955-018-0978-8
• A.E. Attema, W.B.F. Brouwer & K. Claxton (2018). Discounting in economic evaluations. Pharmacoeconomics (Print), 36 (7), 745-758. doi: 10.1007/s40273-018-0672-z
• A.E. Attema, H.M. Krol, N.J.A. van Exel & W.B.F. Brouwer (2018). New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year.European Journal of Health Economics (HEPAC), 19 (2), 277-291. doi: https://doi.org/10.1007/s10198-017-0883-9
• P.H.M. van Baal, A. Morton, D. Meltzer & W.B.F. Brouwer (2018). Future unrelated medical costs need to be considered in cost effectiveness analysis. European Journal of Health Economics (HEPAC). doi: 10.1007/s10198-018-0976-0
• P.H.M. van Baal, A. Morton & J.L. Severens (2018). Health care input constraints and cost effectiveness analysis decision rules.Social Science & Medicine, 200 (March), 59-64. doi: 10.1016/j.socscimed.2018.01.026.
• F.C.W. van Krugten, M. Goorden, A.J.L.M. van Balkom, J. Spijker, W.B.F. Brouwer & L. Hakkaart-van Roijen (2018). Indicators to facilitate the early identification of patients with major depressive disorder in need of highly specialized care: A concept mapping study. Depression and Anxiety, 35 (4), 346-352. doi: https://onlinelibrary.wiley.com/doi/abs/10.1002/da.22741
• J.H. Vermaire & N.J.A. van Exel (2018). Parental attitudes towards oral health and caries-risk in their children. International Journal of Dental Hygiene. doi: https://doi.org/10.1111/idh.12296
• T. Rouyard, A.E. Attema, R. Baskerville, J. Leal & A. Gray (2018). Risk attitudes of people with ‘manageable’ chronic disease: An analysis under prospect theory. Social Science & Medicine, 214, 144-153. doi: 10.1016/j.socscimed.2018.08.007
• Lipman, S.A., Brouwer, W.B.F. & Attema, A.E. (2018). A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health states. European Journal of Health Economics (HEPAC). doi: 10.1007/s10198-018-1008-9
• W.B.F. Brouwer, P.H.M. van Baal, N.J.A. van Exel & M.M. Versteegh (2018). When is it too expensive? Cost-effectiveness thresholds and health care decision-making. Journal of Health Economics (HEPAC). doi: 10.1007/s10198-018-1000-4
• M. Gheorghe, R.J. Hoefman, M.M. Versteegh & N.J.A. van Exel (2018). Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool. Pharmacoeconomics (Print). doi: 10.1007/s40273-018-0706-6
• T. Rouyard, A.E. Attema, R. Baskerville, J. Leal & A. Gray (2018). Risk attitudes of people with ‘manageable’ chronic disease: An analysis under prospect theory. Social Science & Medicine, 214, 144-153. doi: 10.1016/j.socscimed.2018.08.007
• Lipman, S.A., Brouwer, W.B.F. & Attema, A.E. (2018). A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health states. European Journal of Health Economics (HEPAC). doi: 10.1007/s10198-018-1008-9
• W.B.F. Brouwer, P.H.M. van Baal, N.J.A. van Exel & M.M. Versteegh (2018). When is it too expensive? Cost-effectiveness thresholds and health care decision-making. Journal of Health Economics (HEPAC). doi: 10.1007/s10198-018-1000-4
• M. Gheorghe, R.J. Hoefman, M.M. Versteegh & N.J.A. van Exel (2018). Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool. Pharmacoeconomics (Print). doi: 10.1007/s40273-018-0706-6

• Baltussen, R., Bijlmakers, L., Jansen, M., Project Team, 2018. Draagvlak voor lastige keuzes. Eindrapport van het Burgerforum ‘Keuzes in de zorg’
• H. Mason, M. Collins, N. McHugh, J. Godwin, N.J.A. van Exel, C. Donaldson & R. Baker (2018). Is "end of life" a special case? Connecting Q with survey methods to measure societal support for views on the value of life-extending treatments. Health Economics. doi: https://doi.org/10.1002/hec.3640
• N. McHugh, R. Baker, N.J.A. van Exel, H. Mason, J. Godwin, M. Collins & C. Donaldson (2018). Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints. Social Science & Medicine, 198, 61-69. doi: https://doi.org/10.1016/j.socscimed.2017.12.019
• V.T. Reckers, N.J.A. Van Exel & W.B.F. Brouwer (2018). Looking back and moving forward: On the application of proportional shortfall in healthcare priority setting in the Netherlands.Opent extern Health Policy, 122 (6), 621-629. doi: 10.1016/j.healthpol.2018.04.001
• V.T. Reckers, N.J.A. Van Exel & W.B.F. Brouwer (2018). Who should receive treatment? An empirical enquiry into the relationship between societal views and preferences concerning healthcare priority setting.Opent extern PLoS One (online), 13 (6):e0198761. doi: 10.1371/journal.pone.0198761